NESS ZIONA, Israel, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development pharmaceutical company focused on introducing innovative long-acting depot ...
The MarketWatch News Department was not involved in the creation of this content. NESS ZIONA, Israel, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical ...
NESS ZIONA, Israel, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development pharmaceutical company focused on introducing innovative long-acting depot ...
NESS ZIONA, Israel, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting ...
Mapi Pharma is nothing if not persistent. Having tried and failed twice to pull off an IPO on Nasdaq, the Israeli biopharma has arrived on Wall Street yet again in pursuit of $57.5 million (€51.2 ...
NESS ZIONA, Israel, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting ...
Faster, Simpler, Better: Dramatically Reduce Timelines, Simplify Study Start up, and Increase Quality in Hundreds of Clinical Trials Each Year “This new collaboration with MRT will seek to solve two ...
Mylan to invest an additional $20M in Mapi Pharma in support of continued progress on Phase 3 clinical studies “Mapi Pharma and Mylan share a commitment to improve the lives of MS patients, and I am ...
Management to Participate in the 44th Annual J.P. Morgan Healthcare Conference NESS ZIONA, Israel, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results